Valeant sells iNova Pharmaceuticals for $930 million

Selling iNova part of Valeant's efforts to simplify and strengthen its balance sheet.

"The sale of iNova is part of the company's ongoing efforts to both simplify our operating model and strengthen our balance sheet," said Joseph C. Papa Chairmand and CEO, Valeatnt. "We will continue to evaluate opportunities that will enable us to deliver on our commitments and unlock value for shareholders."

iNova, which markets a diversified portfolio of prescription and over-the-counter products in several areas, such as weight management, pain ma, operates in more than 15 countries around the world. iNova holds leading market positions in Australia and South Africa and has an established platform in Asia. Valeant will maintain a strong footprint in these countries primarily through its its Bausch + Lomb franchise.

Valeant will use proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility. The transaction is expected to close in the second half of 2017, subject to customary closing conditions, including receipt of applicable regulatory approvals.